CSIMarket
 


Forty Seven Inc   (FTSV)
Other Ticker:  
 
 

FTSV's Operating Income Growth by Quarter and Year

Forty Seven Inc 's Operating Income results by quarter and year




FTSV Operating Income (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December -24.56 39.33 0.00 0.00
III Quarter September -16.37 -22.37 0.00 0.00
II Quarter June -23.89 -16.96 0.00 0.00
I Quarter March -23.71 0.00 0.00 0.00
FY   -88.53 0.00 0.00 0.00



FTSV Operating Income fourth quarter 2019 Y/Y Growth Comment
Forty Seven Inc in the fourth quarter 2019 recorded Operating Loss of $ -24.56 millions.

According to the results reported in the fourth quarter 2019, Forty Seven Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Forty Seven Inc ' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2019.

Explain Operating Income growth


FTSV Operating Income ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Forty Seven Inc 's fourth quarter 2019 Operating Income $ -24.56 millions FTSV's Income Statement
Forty Seven Inc 's fourth quarter 2018 Operating Income $ 39.33 millions Quarterly FTSV's Income Statement
New: More FTSV's historic Operating Income Growth >>


FTSV Operating Income (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Forty Seven Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FTSV's IV. Quarter Q/Q Operating Income Comment
IV. Quarter 2019 accomplishment of -24.56 millions by Forty Seven Inc come out even less good if you take a look at -16.37 millions Operating Loss a quarter before.

Within Major Pharmaceutical Preparations industry Forty Seven Inc achieved highest sequential Operating Income growth. While Forty Seven Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FTSV's IV. Quarter Q/Q Operating Income Comment
Current accomplishment of -24.56 millions by Forty Seven Inc look even more unfavourable considering the -16.37 millions a quarter before.

Within Major Pharmaceutical Preparations industry Forty Seven Inc achieved highest sequential Operating Income growth. While Forty Seven Inc 's Operating Income growth quarter on quarter, overall rank is .


Forty Seven Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
Cumulative Operating Income 12 Months Ending $ -88.53 $ -24.64 $ -30.64 $ -23.71 $ 0.00
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Forty Seven Inc ' has realized cumulative trailing twelve months Operating Loss of $ -89 millions in the Dec 31 2019 period.
The business is worsening as the cumulative Operating Loss is getting bigger from $ -24.64 millions for the period from Sep 30 2019 to Dec 31 2018 and $ millions for the twelve months ending in the quarter Dec 31 2018 Evelyn P. Miller wrote.

Forty Seven Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Forty Seven Inc ' has realized cumulative trailing twelve months Operating Loss of $ -89 millions in the Dec 31 2019 period.
The results are worsening as the cumulative Operating Loss is inflating from $ -24.64 millions in TTM ending quarter Sep 30 2019 and $ millions for the twelve months ending in the quarter Dec 31 2018.

Forty Seven Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
FTSV's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for FTSV's Competitors
Operating Income Growth for Forty Seven Inc 's Suppliers
Operating Income Growth for FTSV's Customers

You may also want to know
FTSV's Annual Growth Rates FTSV's Profitability Ratios FTSV's Asset Turnover Ratio FTSV's Dividend Growth
FTSV's Roe FTSV's Valuation Ratios FTSV's Financial Strength Ratios FTSV's Dividend Payout Ratio
FTSV's Roa FTSV's Inventory Turnover Ratio FTSV's Growth Rates FTSV's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2019
Prestige Consumer Healthcare Inc -1.47%$ -1.466 millions
Taro Pharmaceutical Industries Ltd-2.25%$ -2.250 millions
Cyclacel Pharmaceuticals Inc -2.73%$ -2.725 millions
Atrion Corporation-2.91%$ -2.909 millions
National Healthcare Corp-4.05%$ -4.054 millions
Koninklijke Philips Nv-4.36%$ -4.363 millions
Gilead Sciences Inc -4.46%$ -4.458 millions
Innoviva Inc -4.64%$ -4.637 millions
Vascular Biogenics Ltd -4.89%$ -4.893 millions
Msa Safety Incorporated-5.36%$ -5.364 millions
Merck and Co Inc -5.42%$ -5.416 millions
Lhc Group Inc -6.24%$ -6.242 millions
Pacific Health Care Organization Inc -7.48%$ -7.484 millions
Purple Biotech Ltd -8.56%$ -8.561 millions
Hologic Inc-11.17%$ -11.174 millions
Regeneron Pharmaceuticals Inc -13.41%$ -13.407 millions
Amgen Inc -14.02%$ -14.022 millions
Harvard Bioscience Inc-15.04%$ -15.040 millions
Fresenius Medical Care Ag-16.32%$ -16.324 millions
Antares Pharma Inc -17.99%$ -17.988 millions
Iqvia Holdings Inc -19.81%$ -19.807 millions
Phibro Animal Health Corporation-23.72%$ -23.718 millions
3m Company-25.69%$ -25.687 millions
Lantheus Holdings Inc -26.59%$ -26.589 millions
Alpha Pro Tech Ltd -28.07%$ -28.070 millions
Lemaitre Vascular Inc -31.49%$ -31.489 millions
Sanofi-33.17%$ -33.169 millions
Pfizer Inc-33.61%$ -33.607 millions
Boston Scientific Corporation-34.17%$ -34.169 millions
Conmed Corporation-35.31%$ -35.315 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com